Why Amyris Stock Was Driven Into the Ground on Wednesday
Synthetic-biology company Amyris (NASDAQ: AMRS) had an absolutely awful day on the stock exchange Wednesday, due to an earnings report that fell well short of expectations. After market hours on Tuesday, Amyris divulged its third-quarter results. Alas, the total fell far short of the average analyst estimate of just under $112 million.